Fundraising FoxAdenocyte
Haifa, IL · 1 known investors
Find your way into Adenocyte
Sign up to see every warm intro you have to Adenocyte
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adenocyte team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Adenocyte develops LINFU (Low Intensity Non-Focused Ultrasound), a minimally invasive ultrasound technology for routine screening of the pancreas to detect pancreatic dysplasia and early-stage pancreatic cancer. The company serves clinical cancer screening for elevated- and average-risk patients, with laboratories in Haifa and Jerusalem and clinical development at the Technion and North American screening centers.
Founders & leadership
MR
Mark RutenbergFounder & CEOMark Rutenberg holds a Ph.D. in Regulatory Biology from Cleveland State University and the Cleveland Clinic, and an M.S.E.E. from Cleveland State University. Over thirty years of work combining electrical engineering and medicine has included developing AI-assisted cervical cytology screening (adopted by over 80 major U.S. laboratories), founding a company applying similar detection methods to head and neck cancer (deployed in over 500,000 patients), and developing WATS3D for Barrett's Esophagus detection (included in ASGE standard-of-care guidelines in 2019); he now serves as founder and CEO of Adenocyte, developing ultrasound screening for early pancreatic cancer detection.
AC
April CarpenterChief Commercial Officer
RH
Robert HarowChief Financial Officer
FS
F. Scott CorbettChief Medical Officer
DE
Drore EisenMedical Research Director
DA
Dan AdamChief Technology Officer
Board
SK
Scott KormanBoard director
Investors · 1
iGan Partnerslisted by iGan PartnersToronto · $365K – $2.2M
How we know: iGan Partners's portfolio page · funding news · press coverage · Not right? Tell us
Related companies · 2
Rarecyte
Incyte CorporationIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
Companies working in the same space as Adenocyte.
In the news
Frequently asked questions
- What does Adenocyte do?
- Adenocyte develops LINFU (Low Intensity Non-Focused Ultrasound), a minimally invasive ultrasound technology for routine screening of the pancreas to detect pancreatic dysplasia and early-stage pancreatic cancer. The company serves clinical cancer screening for elevated- and average-risk patients, with laboratories in Haifa and Jerusalem and clinical development at the Technion and North American screening centers.
- Who founded Adenocyte?
- Adenocyte was founded by Mark Rutenberg.
- Who are Adenocyte's investors?
- Adenocyte's investors include iGan Partners.
- Where is Adenocyte headquartered?
- Adenocyte is headquartered in Haifa, IL.